Business
Qilian International Holding Group Limited Releases 2022 Chairman Letter
JIUQUAN, China, Jan. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or
About this update from Bgm Group Ltd.
[{"type":"text","content":"JIUQUAN, China, Jan. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the \"Company\", \"Qilian International\", \"we\", \"our\" or \"us\"), a China-based pharmaceutical and chemical products manufacturer, today released a letter to shareholders from the Chairman of the Company's board of directors.\nDear Shareholders,\nAs a well-established manufacturer with a long history in the Chinese pharmaceuticals and chemical industry, the Company was officially listed on Nasdaq Global Market (\"Nasdaq\") in January 2021. The Company was the first company to be headquartered in Gansu Province and the first company in the oxytetracycline industry in China to be listed in the U.S. The successful listing of the Company's securities on Nasdaq may attract international investors' attention and facilitate the Company's rapid business development. On the first anniversary of the Company's listing on Nasdaq, on behalf of the Company's Board of Directors, I would like to express my sincere appreciation to all shareholders for their understanding, trust, and support for the Company in the challenging year of 2021.\nQilian International has a large portfolio of products including licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company maintains production facilities in Jiuquan City of Gansu Province, Chengdu City of Sichuan Province, and Rugao City of Jiangsu Province in China. Each subsidiary has high production efficiency, the stable and reliable product quality, and a nationwide marketing network. In 2021, we further strengthened our corporate governance and optimized infrastructure to make sure the progress of our projects. We have also expanded into new markets, and enhanced our brand reputation and product recognition. Specifically, our achievements in 2021 included: the listing of two of our brands, \" Qilian Shan®\" and \" Gan Di Xin®\", on the List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province; the entry into a new heparin sodium project; completing the first phase of organic fertilizer development, which has been commenced production; and the research and development of nitrofurantoin enteric-coated tablets, vitacoenzyme, and others.\nWe expect...